Search

Astellas Pharma Inc.
  • Top MenuAbout
    Corporate Strategic Plan 2021
    Corporate Strategic Plan 2021 (CSP2021) maps the next five years of our journey.
    Read More
    • From the CEO
    • Philosophy
      • Astellas Charter of Corporate Conduct, Group Code of Conduct
    • VISION
    • At a Glance
      • Subsidiaries & Locations
      • Our Business
      • Main Products
      • History
      • Management
    • Board of Directors
    • Global Management Structure
    • Corporate Governance Materials
      • Risk Management
    • Policies & Position Statements
    • Ethics & Compliance
      • Structure to Promote Ethics and Compliance
      • Primary Areas of Focus
      • Elements of Astellas’ Global Ethics & Compliance Program
      • Enhancing and Sustaining an Ethical and Compliant Culture at Astellas
      • Astellas awarded Compliance Leader Verification™
  • Top MenuInnovation
    Innovation
    We pursue cutting-edge science to continuously provide innovative treatment options.
    Read More
    • R&D Strategy
      • Drug Research
      • Major Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Grants for Education and General Research
        • Grants to HCOs to Support HCP Attendance at Congresses
    • Areas of Interest
      • Primary Focus
        • Genetic Regulation
        • Immuno-Oncology
        • Blindness & Regeneration
        • Mitochondria
        • Targeted Protein Degradation
      • Primary Focus Candidates
        • Immune Homeostasis
      • Exploratory Research
        • Targeted Therapeutics for Auditory Regeneration
        • Autophagy
        • Bispecific Immune Cell Engager
        • Engineered Phage Therapy
        • Specific Treg
        • Direct Reprogramming
        • Innate Immune Regulation
        • Circadian Rhythm Regulation
      • Cell Therapy
    • Digital Transformation
      • DX Initiatives Throughout the Value Chain
      • Data, Information and Advanced Analytics
    • New Healthcare Solutions Beyond Medicine (Rx+®)
      • Investigational Near-Infrared Fluorescence Imaging Agent
      • Clinically Relevant Holistic Solutions Mobile Healthcare Application
      • Innovation of Chronic Heart Failure Patient Management
    • Open Innovation in Drug Discovery Research
      • Our Philosophy of Open Innovation
      • Our Labs
        • SakuLab-Tsukuba
        • TME iLab
    • Partnering
  • Top MenuInvestors
    Investor Relations
    You can access to IR related information including IR Library, Financial Information, Corporate Strategic Plan.
    Read More
    • Topics
      • Corporate Strategic Plan 2021
      • Integrated Report
        • Archives
      • Astellas’ ESG Initiatives
    • Financial Information
    • IR Library
      • Business Results
      • Overview of R&D Pipeline
      • IR Meetings
      • Consolidated Financial Statements and Footnotes
      • Corporate Governance Materials
    • IR Calendar
    • Stock & Rating Information
      • Shareholders Meeting
      • Shareholder Return
      • Current Share Status
      • Chart
      • Issuer Rating
      • Analyst Coverage
    • Cautionary Statement
    • Introducing Astellas to Individual Investors
  • Top MenuSustainability
    Sustainability Direction
    We have set Med-term Priorities, Initiatives, and Our Commitments by FY2025 as for Two pillars and Environmental Sustainability.
    Read More
    • Message from CEO
    • Sustainability Approach
      • Sustainability Governance
      • Key Issues and Materiality
      • Sustainability Direction
      • ISO26000
      • Astellas’ SDG Initiatives
      • United Nations Global Compact
      • Stakeholder Communications
      • Awards & Recognition
    • Access to Health
      • Access to Health of Astellas
      • Access to Medicines
      • Healthcare Systems Strengthening
        • Program in Mexico
        • Program in Dominican Republic
        • Program in Peru
        • Program in Malaysia
      • Research Activity on Malaria
      • Research Activities on NTDs
      • Development for Schistosomiasis
      • GHIT Fund
      • Patient Support Activity
      • Working together to bring “medical-eco” activities to drug discovery in Japan
      • Medical Science Advancement
      • Astellas Global Health Foundation
      • Access to Medicine Index Report
    • Environment
      • Environment Initiatives
      • EHS Management
        • ISO certification status of Astellas production sites
      • Environmental Action Plan and Compliance
      • Climate Change Measures
        • Scope 3 emissions (past 3 years)
        • Former Environmental Action Plan
      • Disclosure based on TCFD
      • Energy Consumption
      • Sustainable Biodiversity
        • Biodiversity and Astellas An Enlarged Version
        • The Biodiversity Burden Index and Revenue
      • Resource Recycling
      • Preventing Pollution
        • Further information on PRTR system
      • Environmental Impact of Products and Countermeasures
      • Archive (EHS Report)
      • Environmental Accounting
        • Environment-related Investments and Expenses
      • Reporting coverage, methods
    • Astellas and Society
      • Our People
        • HR Vision, Talent and Organization Management
        • Engagement and Diversity, Equity & Inclusion
        • Occupational Health & Safety
        • Promoting Health Management
        • Major Activities and Programs (Japan)
      • Sustainability in Business Practice
        • Sustainable Procurement Initiatives
        • Research Initiatives
        • Clinical Development Initiatives
        • Technological Development and Production Initiatives
        • Distribution and Sales Initiatives
      • Respect for Human Rights
      • Community Engagement
        • Flying Star Fund
        • Employee Contributions to the Local Community
    • Governance
    • ESG Data
      • ESG Data Environment
      • ESG Data Social
      • ESG Data Governance
  • Top MenuNews
    News Room
    Check the latest news and our people's stories.
    Read More
    • ALL News
    • OUR STORIES
    • Media Library

Stakeholders menu

  • Partnering
    • Why Partner with Astellas
    • Partnering Teams
    • Testimonies from our Partners
    • Registration Form
  • Careers
  • Suppliers
  • Contact Us

Common header menu

  • IMPORTANT NOTICE
  • WORLDWIDE
  • GLOBAL
  • 日本
Important Notice

This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.

Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

OK
logo
Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.
(This link opens in a new window)
Cancel Click here to leave this site.
Menopause has been ignored for too long
Menopause has been ignored for too long

Menopause has been ignored for too long

Find out why Astellas is speaking up and shining a light on the symptoms and experiences of people impacted by menopause this World Menopause Day.

View more
Financial Results

Financial Results for Q2/FY2023

We announced our financial results for Q2/FY2023 on November 1st. Presentation material, video, and meeting script are available.

Read more
Integrated Report 2023

Integrated Report 2023

Please check the latest Integrated Report. (former Annual Report)

Read more
From the CEO

From the CEO

I will make every effort to navigate Astellas with speed and a sense of urgency that “our patients are waiting.”

Read more
Latest News
Dec 04, 2023General News
Astellas Updates “Contact for Potential Acquisition of Astellas’ R&D Programs” Section on its Corporate Website
Dec 01, 2023Press Releases
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Nov 30, 2023Press Releases
Astellas’ Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
EXPLORE ALL NEWS
About us

About us

Astellas aims to stand on the forefront of healthcare change to turn innovative science into VALUE for patients.

Read more
R & D Strategy

R & D Strategy

Astellas’ Focus Area approach supports our commitment to continuous innovation and the creation of innovative therapies that directly address the underlying causes of disease.

Read more
Astellas and Sustainability

Sustainability

We are developing a sustainable society by leveraging Astellas’ strengths and capabilities.

Read more


 

Partnering with Astellas
Partnering with Astellas

Partnering with Astellas

We are actively seeking collaboration opportunities with external partners.

Read More
Careers
Investor Relations

Investor Relations

Read More
LinkedIn

Astellas Pharma’s official LinkedIn

We share the latest information and topics.

Follow us

Modern Slavery Act 2015

Contact for Potential Acquisition of Astellas’ R&D programs.

footer logofooter solgan

Follow us on social media

Linkedin Logo Youtube Logo

Bottom footer menu

  • SITE MAP
  • PRIVACY NOTICE
  • COOKIES POLICY
  • ACCESSIBILITY
  • TERMS OF USE
  • CONTACT US
  • DISASTER INFORMATION FOR EMPLOYEES
© Astellas Pharma Inc.

Update cookie preferences